Zobrazeno 1 - 10
of 1 599
pro vyhledávání: '"Hollebecque A"'
Autor:
Damien Vasseur, Ludovic Bigot, Kristi Beshiri, Juan Flórez-Arango, Francesco Facchinetti, Antoine Hollebecque, Lambros Tselikas, Mihaela Aldea, Felix Blanc-Durand, Anas Gazzah, David Planchard, Ludovic Lacroix, Noémie Pata-Merci, Catline Nobre, Alice Da Silva, Claudio Nicotra, Maud Ngo-Camus, Floriane Braye, Sergey I. Nikolaev, Stefan Michiels, Gérôme Jules-Clement, Ken André Olaussen, Fabrice André, Jean-Yves Scoazec, Fabrice Barlesi, Santiago Ponce, Jean-Charles Soria, Benjamin Besse, Yohann Loriot, Luc Friboulet
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-16 (2024)
Abstract Background Understanding the resistance mechanisms of tumor is crucial for advancing cancer therapies. The prospective MATCH-R trial (NCT02517892), led by Gustave Roussy, aimed to characterize resistance mechanisms to cancer treatments throu
Externí odkaz:
https://doaj.org/article/e6a5668f34d34175ab097af1e5bb22e4
Autor:
Sophie Cousin, Jean-Philippe Guégan, Kohei Shitara, Lola Jade Palmieri, Jean Philippe Metges, Simon Pernot, Shota Fukuoka, Shohei Koyama, Hiroyoshi Nishikawa, Carine A. Bellera, Antoine Adenis, Carlos A. Gomez-Roca, Philippe Alexandre Cassier, Antoine Hollebecque, Coralie Cantarel, Michèle Kind, Isabelle Soubeyran, Lucile Vanhersecke, Alban Bessede, Antoine Italiano
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-11 (2024)
Abstract Anti-angiogenic agents elicit considerable immune modulatory effects within the tumor microenvironment, underscoring the rationale for synergistic clinical development of VEGF and immune checkpoint inhibitors in advanced gastric cancer (AGC)
Externí odkaz:
https://doaj.org/article/092395fd8b914e7cbe0ceb717ec9a6b5
Autor:
Antonin Levy, Daphné Morel, Matthieu Texier, Roger Sun, Jerome Durand-Labrunie, Maria E Rodriguez-Ruiz, Severine Racadot, Stéphane Supiot, Nicolas Magné, Stacy Cyrille, Guillaume Louvel, Christophe Massard, Loic Verlingue, Fanny Bouquet, Alberto Bustillos, Lisa Bouarroudj, Clément Quevrin, Céline Clémenson, Michele Mondini, Lydia Meziani, Lambros Tselikas, Rastilav Bahleda, Antoine Hollebecque, Eric Deutsch
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-13 (2024)
Abstract Background Immuno-radiotherapy may improve outcomes for patients with advanced solid tumors, although optimized combination modalities remain unclear. Here, we report the colorectal (CRC) cohort analysis from the SABR-PDL1 trial that evaluat
Externí odkaz:
https://doaj.org/article/e2332711ee644fd79fb6e8ed2a5b6190
Autor:
Boilève, Alice, Cartry, Jérôme, Goudarzi, Negaar, Bedja, Sabrina, Mathieu, Jacques R.R., Bani, Mohamed-Amine, Nicolle, Rémy, Mouawia, Ali, Bouyakoub, Ryme, Nicotra, Claudio, Ngo-Camus, Maud, Job, Bastien, Lipson, Karélia, Boige, Valérie, Valéry, Marine, Tarabay, Anthony, Dartigues, Peggy, Tselikas, Lambros, de Baere, Thierry, Italiano, Antoine, Cosconea, Simona, Gelli, Maximiliano, Fernandez-de-Sevilla, Elena, Annereau, Maxime, Malka, David, Smolenschi, Cristina, Ducreux, Michel, Hollebecque, Antoine, Jaulin, Fanny
Publikováno v:
In Gastroenterology October 2024 167(5):961-976
Autor:
Damien Vasseur, Ahmadreza Arbab, Fabiola Giudici, Christophe Marzac, Stefan Michiels, Marco Tagliamento, Arnaud Bayle, Cristina Smolenschi, Madona Sakkal, Mihaela Aldea, Hela Sassi, Filippo Gustavo Dall’Olio, Noémie Pata-Merci, Sophie Cotteret, Alice Fiévet, Nathalie Auger, Luc Friboulet, Francesco Facchinetti, Arthur Géraud, Santiago Ponce, Antoine Hollebecque, Benjamin Besse, Jean Baptiste Micol, Antoine Italiano, Ludovic Lacroix, Etienne Rouleau
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-10 (2024)
Abstract Next-generation sequencing (NGS) assays based on plasma cell-free DNA (cfDNA) are increasingly used for clinical trials inclusion. Their optimized limit of detection applied to a large number of genes leads to the identification of mutations
Externí odkaz:
https://doaj.org/article/4130073b97594d488656afc4bdbd62db
Autor:
A. Gueiderikh, A. Tarabay, M. Abdelouahab, C. Smolenschi, M. L. Tanguy, M. Valery, D. Malka, T. Pudlarz, A. Fuerea, V. Boige, A. Hollebecque, M. Ducreux, A. Boilève
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Background Chemotherapy for metastatic pancreatic adenocarcinoma (PDAC) primarily relies on FOLFIRINOX (LV5FU- irinotecan – Oxaliplatine) and Gemcitabine – Nab-Paclitaxel in the first-line setting. However, second-lines remain less well-
Externí odkaz:
https://doaj.org/article/e5f7b5644b2c4637aa097989c3d41b58
Autor:
Clémence Astier, Carine Ngo, Léo Colmet-Daage, Virginie Marty, Olivia Bawa, Claudio Nicotra, Maud Ngo-Camus, Antoine Italiano, Christophe Massard, Jean-Yves Scoazec, Cristina Smolenschi, Michel Ducreux, Antoine Hollebecque, Sophie Postel-Vinay
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-6 (2024)
Abstract Biliary tract cancers (BTCs) are heterogeneous malignancies with dismal prognosis due to tumor aggressiveness and poor response to limited current therapeutic options. Tumor exome profiling has allowed to successfully establish targeted ther
Externí odkaz:
https://doaj.org/article/0e99e403d1d04ae1bc389c998b7b3798
Autor:
Géraud, Arthur, Hueso, Thomas, Laparra, Ariane, Bige, Naike, Ouali, Kaissa, Cauquil, Cécile, Stoclin, Annabelle, Danlos, François-Xavier, Hollebecque, Antoine, Ribrag, Vincent, Gazzah, Anas, Goldschmidt, Vincent, Baldini, Capucine, Suzzoni, Steve, Bahleda, Rastislav, Besse, Benjamin, Barlesi, Fabrice, Lambotte, Olivier, Massard, Christophe, Marabelle, Aurélien, Castilla-Llorente, Cristina, Champiat, Stéphane, Michot, Jean-Marie
Publikováno v:
In European Journal of Cancer July 2024 205
Autor:
Vogel, A., Sahai, V., Hollebecque, A., Vaccaro, G.M., Melisi, D., Al Rajabi, R.M., Paulson, A.S., Borad, M.J., Gallinson, D., Murphy, A.G., Oh, D.-Y., Dotan, E., Catenacci, D.V., Van Cutsem, E., Lihou, C.F., Zhen, H., Veronese, M.L., Abou-Alfa, G.K.
Publikováno v:
In ESMO Open June 2024 9(6)
Autor:
A. Boilève, A. Rousseau, M. Hilmi, A. Tarabay, J.R.R. Mathieu, J. Cartry, S. Bedja, N. Goudarzi, C. Nicotra, M. Ngo-Camus, V. Boige, M. Valéry, T. Pudlarz, M.-A. Bani, P. Dartigues, L. Tselikas, A. Italiano, S. Cosconea, M. Gelli, E. Fernandez-de-Sevilla, D. Malka, M. Annereau, F. Jaulin, C. Smolenschi, A. Hollebecque, M. Ducreux
Publikováno v:
ESMO Gastrointestinal Oncology, Vol 3, Iss , Pp 100030- (2024)
Background: How distinct KRAS alterations in pancreatic adenocarcinoma (PDAC) influence tumor initiation and outcomes remains unclear. Moreover, KRAS is now partly targetable with novel specific inhibitors targeting KRASG12 (G12C or G12D), but specif
Externí odkaz:
https://doaj.org/article/46db6f15ea144e95b0ac4df88d602e00